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ABSTRACT Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite
recent advances in the treatment is, at present, the major cause of death. Today, an early diagnosis of ILD
is possible, and is mandatory to improve the prognosis of the disease.
Pulmonary function tests and high-resolution computed tomography remain the mainstay for the
diagnosis of SSc-ILD, but there is a growing interest in lung ultrasound. Recently, the correlation between
severity of fibrosis and some peripheral blood biomarkers has been described.
Nonselective immunosuppressors are still the main treatment for ILD, with cyclophosphamide (CYC)
most widely used to obtain remission. Novel therapies towards specific molecular and cellular targets have
been suggested; in particular, rituximab (RTX) has shown promising results, but further research is
needed. It is of paramount importance to define the severity of the disease and the risk of progression in
order to define the need for treatment and the treatment intensity. We propose the division of the
treatment strategies at our disposal to induce remission into three categories: high intensity
(haematopoietic stem cell transplantation), medium intensity (CYC and RTX) and low intensity
(azathioprine (AZA) and mycophenolate mofetil (MMF)). After obtaining remission, maintenance
treatment with AZA or MMF should be started.
In this review we explore new advances in the pathogenesis, diagnosis and treatment of SSc-ILD.
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Early diagnosis of ILD is possible, and is mandatory to improve the prognosis of the disease
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The relevance of interstitial lung disease in systemic sclerosis
Pulmonary disease in systemic sclerosis (SSc) mainly comprises interstitial lung disease (ILD) and
pulmonary arterial hypertension (PAH). Over the past 40 years the SSc mortality rate has not changed
significantly [1]. Nevertheless, while the frequency of deaths due to renal crisis has significantly decreased
from 42% to 6%, the proportion of deaths due to ILD and PAH has increased [2]. In fact, ILD and
PAH are the two main causes of death in SSc, accounting for 33% and 28% of deaths, respectively [2].
A European Scleroderma Trials and Research group (EUSTAR) analysis revealed, in a cohort of 3656 SSc
patients, that ILD is present in 53% of cases with diffuse cutaneous SSc and in 35% of cases with limited
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cutaneous SSc [3]. Cumulative survival of SSc patients from diagnosis is 84.1% at 5 years and 74.9% at
10 years [4]. The reported survival of SSc-ILD patients is similar to that of patients without ILD at 5 years
while it is significantly lower at 10 years. In fact, the survival of SSc-ILD patients is reported to be 29–69%
at 10 years [5]. In early autopsy studies, up to 100% of patients have parenchymal involvement [4], as
many as 90% of patients show interstitial abnormalities on high-resolution computed tomography (HRCT)
[6], and 40–75% have changes in pulmonary function tests (PFTs) [7]. Considering the frequency of lung
involvement in SSc and its impact on the prognosis, it is important to recognise patients with ILD early
and treat them appropriately.
Pathogenesis
The pathogenesis of SSc-ILD is not yet fully understood. Three steps are considered to be involved:
1) persistent and repeated bouts of injury to endothelial cells, 2) activation of innate and adaptive immunity
and 3) fibroblast recruitment/activation, which results in accumulation of extracellular matrix and scarring [8].
Still, the exact pathways and mechanisms are not clear and have been the object of recent studies. A pivotal
role seems to be played by transforming growth factor (TGF)-β which is secreted by platelets, monocytes/
macrophages, T-cells and fibroblasts. The binding of TGF-β to its receptor activates Smad-dependent and
Smad-independent pathways, including the mitogen-activated protein kinases p38 and c-Jun N-terminal
kinase, the lipid kinase phosphoinositol-3-kinase, the tyrosine kinase c-ABL, and the Rho-associated
coiled-coil containing protein kinase [9]. Target genes of Smad-dependent TGF-β signalling are type I
collagen, plasminogen activator inhibitor, α-smooth muscle actin and connective tissue growth factor. Toll-like
receptor (TLR)4 is widely recognised as central to the innate immune response to Gram-negative bacteria, but
it can also be activated by endogenous ligands generated by cellular injury, the autoimmune response and
oxidative stress. In skin and lung biopsies of SSc patients, increased expression of TLR4 has been
demonstrated. TLR4 activation potentiates TGF-β signalling and suppresses antifibrotic microRNA [10].
Telocytes are a peculiar type of stromal cell, which may have a role in the regulation of tissue homeostasis. A
recent study has shown loss of telocytes in the gastric wall, myocardium and lung of SSc patients, suggesting
that this loss may be implicated in the pathogenesis of fibrosis [11]. Recently, elevated levels of interleukin
(IL)-33 have been correlated with the severity of skin and lung fibrosis [12]. Another protein that may be
involved in the pathogenesis of SSc-ILD is caveolin-1. It interferes with the TGF-β pathway since it inhibits
Smad 3 phosphorylation and increases the endocytosis and degradation of TGF-β ligand–receptor complexes.
In SSc patients, low levels of surface caveolin-1 have been detected [13]. Thymosin β-4 is a small ubiquitin
protein, which acts by promoting cell motility and cell adhesion, inhibiting apoptosis, and downregulating
inflammation. Lower levels of thymosin β-4 in the bronchoalveolar lavage of SSc-ILD patients have been
correlated with disease progression [14]. In recent years, some genetic studies have shown increased
expression of the TGF-β response including fibrosis-associated genes and myofibroblast markers [15, 16]. An
analysis of gene expression in skin biopsies identified some transcripts that correlate with the severity of
SSc-ILD. Plasma levels of two proteins encoded by these genes, CCL2 and soluble P-selectin glycoprotein
ligand 1, correlate with forced vital capacity (FVC) in PFTs, suggesting their possible use as biomarkers [17].
Epigenetic mechanisms may also play a role in the pathogenesis of SSc-ILD. Alterations in DNA
methylation and histone modifications have been described in SSc-ILD patients [18]. The role of
epigenetic alterations has not been widely investigated and it represents a challenging research area.
Identification and follow-up of patients with SSc-ILD
The history of patients with SSc-ILD usually reveals the insidious onset of exertional dyspnoea and a
nonproductive cough. Bilateral basilar dry inspiratory crackles are usually present at lung auscultation.
Virtually, all SSc-ILD patients are positive for antinuclear antibodies, which are frequently accompanied by
SSc-specific antibodies, anti-topoisomerase I (anti-Topo I) and anti-Th/To and more rarely by
anti-centromere antibodies [19]. PFTs reveal a restrictive pattern, mainly due to parenchymal involvement,
with reduced forced expiratory volume in 1 s (FEV1) and FVC, and a normal or slightly increased FEV1/FVC
ratio. Restrictive lung disease from severe thoracic cutaneous involvement has been reported. Airway disease,
although described, is rare in SSc as compared with other connective tissue diseases [20]. Diffusing capacity of
the lung for carbon monoxide (DLCO) is the most important functional test due to its ability to investigate the
interstitial space between alveolar and endothelial surfaces as well as the integrity of the lung vascular bed. In
patients with SSc, it can be reduced either in parenchymal fibrosis or in vascular abnormalities of pulmonary
hypertension. Recently a rapid decline of DLCO has been identified as the single most significant marker of
poor outcome [5]. Furthermore, it has been shown that DLCO provides the best estimate of the extent of ILD
on HRCT [21]. Concerning imaging techniques, chest radiography has a low sensitivity and specificity for
detecting parenchymal involvement. By contrast, a good specificity has been demonstrated in pulmonary
hypertension, where typical findings are the enlargement of right pulmonary artery, loss of peripheral
vasculature and filling of the retrosternal space by the hypertrophic right ventricle [22]. For the diagnosis of
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SSc-ILD, HRCT is mandatory. The most frequent HRCT pattern is nonspecific interstitial pneumonia (NSIP)
[23], with a greater proportion of ground-glass opacities (GGOs) and a lower proportion of coarse reticulation.
However, a usual interstitial pneumonia (UIP) pattern, characterised by honeycombing and traction
bronchiectasis, may also be seen. Since the HRCT pattern predicts the underlying histopathology well, a lung
biopsy is not generally necessary. The reversal of HRCT modifications is rarely achieved. GGO is commonly
associated with irreversible disease. In fact, only 5% of patients with GGO and nonfibrotic interstitial opacities
show an improvement of HRCT findings. Thus, in SSc, GGO may represent fibrosis in many cases [24]. Over
time, the radiographic progression involves the replacement of GGOs with honeycombing/traction
bronchiectasis and/or bronchiolectasis [25].
Recently, the issue of X-ray exposure in SSc patients has been raised [26, 27]. For this reason, the use of a
9-slice HRCT protocol has been evaluated in order to reduce the radiation dose and has shown an accuracy
of over 90% when compared with standard HRCT [27]. Quantitative CT densitometry has been proposed as
a method of providing a sensitive assessment of lung structure for monitoring parenchymal damage [28]
and a good correlation with PFTs has been shown [28–30]. In recent years, there has been a growing
interest in lung ultrasound (LUS) as a fast and noninvasive method with no risk of radiation exposure [26,
31]. The ultrasound feature of ILD involves the detection and quantification of the lung comet tail signs
(B-lines) that originate from thickened interlobular septa. The number of B-lines has shown a good
correlation with lung involvement on HRCT [32]. Nevertheless, the role of LUS in reducing the number of
HRCTs in the follow-up of patients awaits further validation [33]. LUS cannot replace HRCT for diagnosis
and for a complete evaluation of lung involvement. We propose an algorithm, reflecting our experience, for
the diagnosis and follow-up of SSc-ILD that may include the use of LUS (fig. 1). This algorithm suggests
that SSc patients should perform PFTs, HRCT and LUS to reach a diagnosis. Patients without lung
involvement should then be monitored every 1–2 years (depending on the presence of risk factors) using
PFTs with DLCO, which are easy to perform, repeatable, reproducible, noninvasive and not expensive, and, if
available, using LUS. If ILD is suspected from these examinations patients should move on to HRCT.
Patients with evidence of ILD-SSc should perform PFTs with DLCO every 6 months and, if available, LUS;
HRCT should be performed if progression of lung disease is suspected.
The outcome and its predictors
Unlike the idiopathic interstitial pneumonias, survival of patients with NSIP does not appear to differ
from that of patients with UIP [5]. Severe restrictive lung disease (defined by a FVC of ⩽50% predicted)
has been reported to occur in 13% of patients [7]. Patients who develop severe ILD tend to have a
progressive decline in lung function within the first 2 years of disease [7]. It is of paramount importance
to identify those patients who will develop severe ILD. Many demographic, clinical and serological features
associated with disease progression have been described: male sex, black ethnicity/race, older age, early
disease, and the presence of anti-Topo I antibodies [5, 34–37].
Suspicion 
of ILD
Therapy
Increase/switch therapy
Suspicion 
of progression
No progression
Progression
HRCT PFT with DLCO every 1–2 years
and lung ultrasound
No SSc-ILD
PFT with DLCO every 6 months
and lung ultrasound
HRCT
PFT with DLCO
Lung ultrasound
HRCT
SSc diagnosis
(clinical examination, capillaroscopy, autoantibodies)
SSc-ILD
FIGURE 1 Algorithm for diagnosis and follow-up of systemic sclerosis-interstitial lung disease (SSc-ILD). PFT: pulmonary
function test; DLCO: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography.
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Recently, an algorithm based on combined evaluation of HRCT and PFTs has been proposed to differentiate
patients with extensive and limited lung disease. Patients with >20% HRCT abnormalities are considered to
have extensive lung disease and those with <20% to have with limited disease. If HRCT evaluation is
inconclusive, patients are considered to be affected by extensive lung disease if FVC <70% predicted and by
limited lung disease if FVC ⩾70% predicted. Patients with extensive lung disease have strikingly higher
mortality and faster deterioration of lung function [38]. A meta-analysis of 26 studies identified male sex,
disease extent on HRCT, presence of honeycombing, elevated Krebs von den Lungen (KL-6) values and
increased alveolar epithelial permeability as predictors of both mortality and ILD progression in unadjusted
analysis, while disease extent on the HRCT scan was the only variable that independently predicted both
mortality and ILD progression [39]. Recently, a loss of density on capillaroscopy was shown to be associated
with worse FVC and DLCO [40] and biomarkers that correlate with the severity of fibrosis have been
proposed: elevated levels of chitinase [41], tenascin C [42], growth differentiation protein 15 [43], cartilage
oligomeric matrix protein, alveolar epithelial cell antigen, KL-6 [44] and the chemokine CXCL4 [45]. Serum
IL-6 predicted early disease progression and IL-6 values >767 pg·mL−1 were predictive of risk of death within
the first 30 months in patients with mild SSc-ILD [46].
Treatment
Since inflammation precedes and leads to fibrosis, and it is believed that only the inflammation is in part
reversible, early treatment is mandatory. Nevertheless, fibrosis is generally the predominant abnormality in
SSc-ILD. In a large histopathological series, inflammatory abnormalities were present in <20% of cases [5].
At present, no treatment can reverse lung fibrosis, and therefore the prevention of disease progression is
still a more realistic goal than disease regression.
When faced with a patient with SSc-ILD, it is of paramount importance to understand the risk of
progression in order to decide if therapy should be started and the level of intensity of the treatment.
Therefore, the physician should make a profile of the patient that includes the stage, the activity and the
severity of the disease. Even if there are no studies showing that extensive disease, as defined by GOH et al.
[38], is a criterion to start treatment, experts will treat patients with extensive disease, while a “wait and
watch” approach is not infrequently chosen when managing patients with mild disease. SSc patients with
evidence of ongoing disease progression, based on pulmonary function decline or radiographic deterioration,
need treatment independent of disease extent. Features that may predict progression (e.g. early disease,
tendon friction rub, anti-Topo I positivity and high IL-6 levels) may in future be considered when deciding
whether or not to start an immunosuppressive therapy.
Nonselective immunosuppressors
Nonselective immunosuppressors are still the most widely used treatment in SSc-ILD. Therapy for ILD
consists of an induction and a maintenance phase (fig. 2).
After two double-blind [47, 48] and one unblinded [49] randomised controlled trials (RCTs), in which
patients treated with cyclophosphamide (CYC) showed either a significant increase or a trend towards an
increase in FVC [47–49], CYC is the drug most used as an induction regimen. Results from the
Scleroderma Lung Study I showed that the beneficial effects of oral CYC persisted or increased for several
months after stopping the therapy, but were no longer apparent after 12 months; suggesting that
maintenance treatment after CYC therapy is needed [47]. When using CYC, toxicity is an issue; in the
short term this includes leukopenia and infections, while long-term effects include infertility, bone marrow
toxicity and carcinogenesis. The use of intermittent intravenous pulses reduces the toxicity [50]. There is
still no agreement on dose, duration and frequency of CYC pulses [48, 51–53]. We suggest the use of
monthly pulses at a dose of 1 g·m−2 for 6–12 months. The dose of each infusion and the duration of the
therapy can be reduced according to age and comorbidity.
Recently, the use of mycophenolate mofetil (MMF) in the treatment of SSc-ILD has produced great
interest. To date, only observational studies on the efficacy of MMF have been performed. A recent
meta-analysis, encompassing one prospective [54] and four retrospective studies [55–58], evaluated the
safety and efficacy of MMF and mycophenolate sodium [59]. The results of this meta-analysis show that
mycophenolate is a safe therapeutic agent and its administration has been linked with stabilisation of lung
functional parameters. A prospective study in which patients treated with MMF were matched 1:1 with
patients treated with CYC, showed a deterioration of lung HRCT at 2 years after MMF treatment but not
after CYC, despite the fact that patients treated with CYC had more extensive ILD at baseline [60]. While
awaiting the results of a multicentre randomised clinical trial, the Scleroderma Lung Study II, which aims
to compare the functional effect of MMF with oral CYC in patients with SSc-ILD, MMF is generally used
as a maintenance treatment after CYC and is only occasionally employed as an induction treatment [61].
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In a RCT, azathioprine (AZA) has been compared with CYC as first line treatment. Unlike patients treated
with CYC who showed a trend towards FVC improvement, in patients receiving AZA a significant
deterioration of both FVC and DLCO was observed after 10 months of follow-up [49]. The results of
observational studies are encouraging concerning the use of AZA as a maintenance agent, as AZA stabilised
lung function in most patients [51, 62, 63]. In view of these results we usually do not recommend the use of
AZA as first-line agent but mainly as a maintenance treatment after CYC. Currently, there are no parameters
to guide the choice between AZA and MMF as the maintenance treatment. In a recent study patients with
deterioration of lung function after CYC received MMF and those with improvement or stabilisation were
treated with AZA. Most of patients unresponsive to CYC also worsened under MMF [51].
Corticosteroids are often used in SSc patients, predominantly in combination with other
immunosuppressive treatments since monotherapy with corticosteroids is generally not effective.
Corticosteroid pulses have been used in association with CYC in the treatment of ILD-SSc with favourable
results [64, 65]. It is important to remember that the chronic use of corticosteroids at a medium-high dose
(>15 mg·day−1) has been associated with a higher risk of developing a scleroderma renal crisis (SRC),
particularly in patients with early diffuse disease [66, 67].
Biological immunotherapies
In terms of biological treatment, interesting results on the use of rituximab (RTX) have been published. A
few years ago, a pilot study randomised 14 diffuse cutaneous SSc patients to receive either RTX plus
standard therapy or standard therapy alone. Two cycles of RTX were administered (at baseline and
24 weeks). Each cycle consisted of four weekly RTX infusions (375 mg·m−2·week−1). After 1 year of
follow-up, patients treated with RTX showed a significant improvement in FVC, DLCO and modified
Rodnan skin score (mRss) [68]. Two further cycles of RTX, at an interval of 6 months, were then
administered to the patients in the RTX group. After 2 years of follow-up, a significant improvement in
pulmonary function (FVC: +9%, p<0.0001; DLCO: +10.88%, p<0.001) and skin involvement was observed
(mRss: −8.63, p<0.0001) [69]. In 2014, a case–control analysis, carried out by the EUSTAR group, was
published. 63 patients treated with RTX were matched with control patients from the EUSTAR database
not treated with RTX. In SSc-ILD patients RTX significantly prevented further decline of FVC compared
with matched controls (p=0.02) [70]. Although the efficacy of RTX is awaiting validation in a RCT, these
results are encouraging and we consider RTX as a valid treatment option in patients who do not tolerate
CYC or who have a contraindication for it. RTX may also be used after CYC instead of starting
maintenance with MMF or AZA, particularly if the patient fails to response to CYC.
As for other biological therapies (abatacept, tocilizumab and anti-tumour necrosis factor (TNF)-α), there
are only a few studies evaluating their efficacy in SSc-ILD. In particular, we do not recommend the use of
anti-TNF-α since its effects on fibrosis are not clear [71].
Diagnosis of SSc-ILD
No
Yes
High intensity: HSCT
Failure
Low intensity: AZA, MMF
Maintenance: AZA, MMF, RTX 
(Continue or shift)
Medium intensity: i.v. CYC, RTX
Lung transplantation
Remission
Define disease extent, activity 
and lung function
Define the intensity of 
treatment to induce remission
FIGURE 2 Algorithm to induce remission in systemic sclerosis-interstitial lung disease (SSc-ILD). HSCT:
haematopoietic stem cell transplantation; CYC: cyclophosphamide; RTX: rituximab; AZA: azathioprine; MMF:
mycophenolate mofetil.
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Antifibrotic treatment
In SSc, no antifibrotic drug has shown a real efficacy in prevention and treatment of fibrosis. The tyrosine
kinase inhibitor, imatinib mesilate, blocks the pro-fibrotic c-Abl kinase, an important downstream
signalling molecule of TGF-β [72]. In two single-arm, open label, phase I/IIa and IIa clinical trials,
patients treated with imatinib showed a significant reduction of mRss. A statistically significant
improvement in lung function was only shown in one of the studies. In both studies adverse events (facial/
lower extremity oedema, fatigue, gastrointestinal and musculoskeletal complaints) were common [73, 74].
In a proof-of-concept, double-blind, RCT, imatinib was interrupted after 6 months due to its poor
tolerability [75]. Only four out of the 10 active diffuse cutaneous SSc patients enrolled were able to
complete the 6 months of treatment. In this study, imatinib was used at a dose of 400 mg twice a day;
however, when the dose was reduced to 200 mg daily it was also poorly tolerated. By contrast, in a very
recent study in which patients received 200 mg daily, imatinib was well tolerated [76]. Imatinib has been
evaluated in a RCT in patients with idiopathic pulmonary fibrosis. In this study imatinib at a dose of
600 mg daily did not affect either survival or lung function. Serious adverse events were not more frequent
in the imatinib group than in the placebo group [77]. Considering the lack of clear evidence of efficacy
and the quite common side-effects, imatinib is rarely used in clinical practice.
Thalidomide has shown antifibrotic properties on interstitial lung fibrosis in in vitro studies of human
fetal lung fibroblasts and in vivo studies of a mouse model of ILD generated by bleomycin injection [78].
Further studies are needed in order to define if it can represent a treatment option for SSc-ILD patients.
Immunoglobulins
The use of intravenous immunoglobulins has been evaluated in a randomised double-blind
placebo-controlled trial and in some open-label studies, in which an improvement of skin involvement was
observed [79–82]. In these studies the effects on ILD were not evaluated. The case of a SSc patient with
myositis and early-stage ILD was recently described, in which, after i.v. immunoglobulins, the regression
of GGOs, septal thickenings and a full recovery of lung function occurred [83].
Haematopoietic stem cell transplantation
In the past decade, intense immunosuppression followed by haematopoietic stem cell transplantation (HSCT)
has emerged as a new therapeutic procedure for patients affected by severe diffuse cutaneous SSc that is
refractory to conventional treatments [84]. Recently, the results of the Autologous Stem Cell Transplantation
International Scleroderma Trial (ASTIS), a phase III, multicentre, randomised study, were published. In this
trial, HSCT was compared, in terms of efficacy and safety, with 12 successive monthly i.v. pulses of CYC. In
terms of effects on lung function, patients undergoing HSCT showed a significant improvement of both FVC
and total lung capacity, while no significant differences in terms of DLCO were observed. The number of
events, defined as death or persistent major organ failure, was recorded in the two groups. Patients
undergoing HSCT showed a higher number of events in the first year: 13 (16.5%) events, including eight
treatment-related deaths, in the HSCT group versus eight (10.4%) events, with no treatment-related deaths, in
the control group. But the total of number of events, observed during a median follow-up of 5.8 years, was
higher in the CYC treated group: 22 events in the HSCT group (19 deaths and three irreversible organ
failures) and 31 events in the CYC group (23 deaths and eight irreversible organ failures). Therefore, HSCT
was associated with increased treatment-related mortality in the first year after treatment, but it conferred a
significant long-term event-free survival benefit and may improve lung function [85]. Nevertheless, before
deciding on transplantation the high treatment-related risk of death should always be considered.
Lung transplantation
Lung transplantation is a life-saving option for SSc-ILD patients who are not responsive to medical
therapy. Unfortunately lung transplantation is not always possible due to the involvement of other organs.
The short- and intermediate-term survival of SSc-ILD patients post-lung transplantation are similar to
those seen in idiopathic pulmonary fibrosis [86]. Considering the main studies on lung and heart–lung
transplantation an overall survival of 52–80% at 2 years is reported [87–90]. In a recent retrospective
analysis a survival rate of 59% is reported at 3 years [91]. The study with the best survival outcomes had
more stringent exclusion criteria [89].There are no official specific contraindications for lung or heart–lung
transplantation in SSc. Independent of the disease that leads to transplantation, absolute contraindications
are: untreatable organ failure other than lung (especially creatinine clearance <50 mL·min−1/1.73 m−2),
non-curable chronic extrapulmonary infections, active or recent neoplasia (less than 2 years), active
smoking or active substance addition, uncontrolled psychiatric disorders, major spinal/thoracic deformity
and degenerative neuromuscular diseases, documented non-adherence with medical therapy, and body
mass index <15 kg·m−2. Recently, specific SSc contraindications have been proposed. They include:
uncontrolled active inflammatory myopathy, active digital ulcers, severe gastrointestinal involvement,
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cardiac arrhythmias, unstable renal function in the past 3 months (except in the case of acute functional
renal failure related to right ventricle dysfunction), an interval of <3 years between SRC and
transplantation, and increased risk of SRC (significant skin breakdown from severe cutaneous disease,
diffuse SSc evolving for <3 years since the first non-Raynaud symptoms) [91].
Conclusions
The early diagnosis of ILD is possible and should be achieved by every specialist. It is not only necessary
to get an early diagnosis, but also to define the severity of the disease and try to predict patients’
prognosis. In this effort, risk factors for evolution should be checked in every patient. According to the
severity of the disease the physician should define how aggressive the therapy should be. Early treatment is
mandatory to achieve a better prognosis. To obtain remission, that is to stop disease progression and, if
possible, to reverse some disease-related changes, is the aim of every treatment strategy. Patients should be
evaluated regularly in order to define if remission has been reached and therapy should be modified if
needed. We propose division of the treatment strategies at our disposal to induce remission into three
classes: high intensity (HSCT), medium intensitiy (CYC and RTX), and low intensity (AZA and MMF).
After obtaining remission, maintenance treatment with AZA or MMF should be started (fig. 2).
Unfortunately, and despite recent advances, in some cases, all the treatments currently at our disposal are
unable to significantly change the natural course of this disease.
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